Copeland Capital Management LLC Reduces Stake in STERIS plc $STE

Copeland Capital Management LLC cut its position in shares of STERIS plc (NYSE:STE) by 4.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 184,511 shares of the medical equipment provider’s stock after selling 8,400 shares during the quarter. Copeland Capital Management LLC owned 0.19% of STERIS worth $45,656,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Spurstone Advisory Services LLC purchased a new position in shares of STERIS in the second quarter valued at $29,000. Geneos Wealth Management Inc. grew its stake in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares during the last quarter. Loomis Sayles & Co. L P purchased a new position in STERIS during the 2nd quarter valued at about $54,000. Generali Investments Management Co LLC purchased a new position in STERIS during the 2nd quarter valued at about $56,000. Finally, CYBER HORNET ETFs LLC acquired a new position in STERIS during the second quarter worth about $62,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Activity at STERIS

In other STERIS news, VP John Adam Zangerle sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the transaction, the vice president owned 33,669 shares of the company’s stock, valued at $8,926,998.66. This trade represents a 30.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel A. Carestio sold 159 shares of STERIS stock in a transaction on Monday, October 6th. The shares were sold at an average price of $241.82, for a total transaction of $38,449.38. Following the completion of the transaction, the chief executive officer owned 51,096 shares in the company, valued at approximately $12,356,034.72. This trade represents a 0.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 25,203 shares of company stock valued at $6,624,667 over the last three months. Insiders own 1.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on STE shares. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $273.50.

STERIS Trading Up 0.3%

Shares of STE opened at $256.10 on Tuesday. STERIS plc has a fifty-two week low of $200.98 and a fifty-two week high of $268.60. The company has a market capitalization of $25.14 billion, a PE ratio of 36.80 and a beta of 1.01. The stock has a fifty day moving average of $254.56 and a two-hundred day moving average of $244.71. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.38 by $0.09. STERIS had a return on equity of 14.43% and a net margin of 12.07%.The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the previous year, the business earned $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, analysts forecast that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Tuesday, November 18th. STERIS’s dividend payout ratio is presently 36.21%.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.